Efficacy you and your patients can see

Some patients see noticeable improvements to the arms, back, hips and/or legs
as early as week 1⁴

More than a foam spray, superior efficacy^1,5

More than half of Enstilar® patients achieved treatment success* at week 4^1,5

*Treatment success is defined as clear or almost clear from baseline moderate to severe disease or clear from baseline mild disease. Requiring at least a 2-step improvement in PGA.

Innovative foam spray application

Watch Winnie Woo, our Senior Medical Science Liasion explain how the foam spray impacts the efficacy of Enstilar®.

Similar tolerability with superior efficacy to Daivobet^®1

Study versus Daivobet® ointment:

The frequency of adverse events, most of which were mild, was low and comparable between the two active treatment groups¹
The most frequently reported adverse reactions during treatment are application site reactions including pain; pruritis and irritation²

“Even with the greater efficacy reported…this is not accompanied with any compromise in safety“¹